icon-charity icon-donate-car icon-energy icon-fundraise icon-shop icon-sponsorships

phase 1

clinical trial

can T cell immunotherapy work in osteosarcoma and nb?

Project Title: Activated T-Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcomas
Researcher: Maxim Yankelevich, MD
Institution: Barbara Ann Karmanos Cancer Institute
Study Type: Phase 1 Clinical Trial
Status: Ongoing

This trial studies the side effects and best dose of activated T-cells armed with GD2 bispecific antibody and how well they work in treating patients with neuroblastoma, osteosarcoma, and other GD2+ solid tumors. This study will provide new information on whether infusions of these activated T-cells will not only kill the tumor, but also "vaccinate" the patients against their own cancer resulting in significant improvement in survival for patients with relapsed GD2-positive tumors.

To learn more about this trial, visit clinicaltrials.gov.

Charity Partners: Fishin’ For The Cure

more clinical trials

Activated T-Cells Transduced with a 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase9 Suicide Safety Switch for Neuroblastoma

Read More >

Improving GD2 T cell Immunotherapy for Patients with Neuroblastoma

Read More >